Effectiveness of corticoid pulses in patients with cytokine storm syndrome
induced by SARS-CoV-2 infection
#MMPMID32835105
Callejas Rubio JL
; Luna Del Castillo JD
; de la Hera Fernández J
; Guirao Arrabal E
; Colmenero Ruiz M
; Ortego Centeno N
Med Clin (Engl Ed)
2020[Aug]; 155
(4
): 159-161
PMID32835105
show ga
INTRODUCTION: Cytokine storm syndrome (CSS) is a serious complication of COVID-19
patients. Treatment is tocilizumab. The use of glucocorticoids (GC) is
controversial. In other very similar CSS, such as macrophage activation syndrome
(MAS) and hemophagocytic syndrome (HFS), the main treatment are corticosteroids.
Our objective is to evaluate the efficacy of GC in the CSS by COVID-19. PATIENTS:
We included 92 patients with CSS associated to COVID-19 who received GC, GC, and
tocilizumab and only tocilizumab. We determine CSS markers. We evaluated
mortality, intubation, and a combined variable. RESULTS: In all cases the
percentages of events were lower in the group of patients with GC was
administered. The hazard ratio of the final variables with GC versus the group in
which only tocilizumab was administered was lower as CGs were considered, with
statistical significance for survival. DISCUSSION: The early use of GC pulses
could control SLC, with a lower requirement to use tocilizumab and a decrease in
events such as intubation and death.
free
free
free
